Exagen Inc. (XGN)
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States.
It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.
The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS.
In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d.
Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.
It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity Institute to develop novel patented biomarkers.
The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
|IPO Date||Sep 19, 2019|
|Industry||Health Care Providers & Services|
1261 Liberty Way Ste C
Vista, California 92081-8356
|Phone||760 560 1501|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Fortunato Rocca||Chief Executive Officer, President and Director|
|Kamal Adawi M.S., MBA||Chief Financial Officer and Corporate Secretary|
|Dr. Debra Jeske Zack||Chief Medical Officer|
|Mark Hazeltine||Chief Operating Officer|
|Dr. Ming-Chou Lee Ph.D.||Chief Technology Officer|
|Dr. Anja Kammesheidt Ph.D.||Chief Scientific Officer|
|John Wegener||Senior Vice President of Sales and Marketing|
Latest SEC Filings
|Jan 10, 2022||8-K||Current report|
|Dec 23, 2021||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Dec 17, 2021||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Nov 10, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Nov 10, 2021||8-K||Current report|
|Oct 25, 2021||8-K||Current report|
|Oct 19, 2021||8-K||Current report|
|Sep 7, 2021||4||Statement of changes in beneficial ownership of securities|
|Aug 27, 2021||8-K||Current report|
|Aug 9, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|View All SEC Filings|